Equipment
Air Science USABio-Chem FluidicsCarl Zeissnano-porous systems limitedNuAireThermo Fisher Scientific Inc
Read MoreScientists recently presented interim results from a prospective trial examining treatment of carcinoma of unknown primary (CUP) site directed by CancerTYPE ID. Interim findings suggest that selecting treatment based on results from the CancerTYPE ID assay leads to median survival of 12.9 months.
Read MoreAspenBio Pharma Inc reported today that the company is performing additional data analysis on its recently completed pivotal clinical trial. As a result, the submission of its 510(k) application for AppyScore with the FDA will not occur as previously anticipated by late June 2010.
Read MoreARKRAYAUDIT MicroControls IncBio-Medical Products CorpQuantimetrix Sysmex AmericaThermo Fisher Scientific Inc
Read MoreResearch and Markets has announced the addition of the “Biomarkers in Breast Cancer 2010” report to their offering.
Read More